Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Measurement of IFN-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2

  • Safont Gonzalez, Guillem|||0000-0001-8174-4279
  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Smalchuk, Daria
  • Stojanovic, Zonan
  • Marín, Alicia|||0000-0002-9358-2120
  • Lacoma, Alicia|||0000-0002-2049-3872
  • Pérez-Cano, Cristina
  • López-Martínez, Anabel
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • Solis, Alan Jhunior
  • Arméstar, Fernando|||0000-0002-6374-1418
  • Matllo, Joan
  • Díaz-Fernández, Sergio
  • Romero, Iris
  • Casas, Irma|||0000-0002-5902-5777
  • Strecker, Kevin
  • Preyer, Rosemarie
  • Rosell Gratacos, Antoni|||0000-0003-0877-7191
  • Latorre, Irene|||0000-0001-8159-2455
  • Domínguez, José|||0000-0001-7888-0309
The study of specific T-cell responses against SARS-CoV-2 is important for understanding long-term immunity and infection management. The aim of this study was to assess the dual IFN-γ and IL-2 detection, using a SARS-CoV-2 specific fluorescence ELISPOT, in patients undergoing acute disease, during convalescence, and after vaccination. We also evaluated humoral response and compared with T-cells with the aim of correlating both types of responses, and increase the number of specific response detection. Blood samples were drawn from acute COVID-19 patients and convalescent individuals classified according to disease severity; and from unvaccinated and vaccinated uninfected individuals. IgGs against Spike and nucleocapsid, IgMs against nucleocapsid, and neutralizing antibodies were also analyzed. Our results show that IFN-γ in combination with IL-2 increases response detection in acute and convalescent individuals (p = 0.023). In addition, IFN-γ detection can be a useful biomarker for monitoring severe acute patients, as our results indicate that those individuals with a poor outcome have lower levels of this cytokine. In some cases, the lack of cellular immunity is compensated by antibodies, confirming the role of both types of immune responses in infection, and confirming that their dual detection can increase the number of specific response detections. In summary, IFN-γ/IL-2 dual detection is promising for characterizing and assessing the immunization status, and helping in the patient management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis

  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Latorre, Irene|||0000-0001-8159-2455
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Martínez-Planas, Aina
  • Minguell Domingo, Laura
  • Vallmanya, Teresa
  • Méndez Hernández, Maria|||0000-0001-5697-2763
  • Soriano-Arandes, Antoni|||0000-0001-9613-7228
  • Baquero-Artigao, Fernando|||0000-0002-6903-3826
  • Rodríguez-Molino, Paula
  • Guillén-Martín, Sara
  • Toro Rueda, Carlos
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Jiménez-Fuentes, María Ángeles|||0000-0001-5181-4192
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Sabriá, Josefina
  • Santos, José Ramón|||0000-0002-0886-7114
  • Puig, Jordi|||0000-0002-4075-0346
  • Domínguez-Álvarez, Marisol
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Altet, Neus
  • Galea, Yolanda
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • García-García, Esther
  • Bach Griera, Marc|||0000-0001-9845-7225
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Julián, Esther|||0000-0002-6558-3978
  • Torrelles, Jordi B.|||0000-0001-7702-5941
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Domínguez, José|||0000-0001-7888-0309
Background: Diagnosis of nontuberculous mycobacteria (NTM) infections remains a challenge. In this study, we describe the evaluation of an immunological NTM-interferon (IFN)-γ release assay (IGRA) that we developed using glycopeptidolipids (GPLs) as NTM-specific antigens. Methods: We tested the NTM-IGRA in 99 samples from pediatric patients. Seventy-five were patients with lymphadenitis: 25 were NTM confirmed, 45 were of unknown etiology but compatible with mycobacterial infection and 5 had lymphadenitis caused by an etiologic agent other than NTM. The remaining 24 samples were from control individuals without lymphadenitis (latently infected with M.Tuberculosis, uninfected controls and active tuberculosis patients). Peripheral blood mononuclear cells were stimulated overnight with GPLs. Detection of IFN-γ producing cells was evaluated by enzyme-linked immunospot assay. Results: NTM culture-confirmed lymphadenitis patient samples had a significantly higher response to GPLs than the patients with lymphadenitis of unknown etiology but compatible with mycobacterial infection (P < 0.001) and lymphadenitis not caused by NTM (P < 0.01). We analyzed the response against GPLs in samples from unknown etiology lymphadenitis but compatible with mycobacterial infection cases according to the tuberculin skin test (TST) response, and although not statistically significant, those with a TST ≥5 mm had a higher response to GPLs when compared with the TST <5 mm group. Conclusions: Stimulation with GPLs yielded promising results in detecting NTM infection in pediatric patients with lymphadenitis. Our results indicate that the test could be useful to guide the diagnosis of pediatric lymphadenitis. This new NTM-IGRA could improve the clinical handling of NTM-infected patients and avoid unnecessary misdiagnosis and treatments.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management

  • Safont Gonzalez, Guillem|||0000-0001-8174-4279
  • Latorre, Irene|||0000-0001-8159-2455
  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Stojanovic, Zorac
  • Marín, Alicia|||0000-0002-9358-2120
  • Pérez-Cano, Cristina
  • Lacoma, Alicia|||0000-0002-2049-3872
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • Solis, Alan Jhurior
  • Arméstar, Fernando|||0000-0002-6374-1418
  • Matllo, Joan
  • Díaz-Fernández, Sergio
  • Cendón Esteve, Arnau
  • Sokalchuk, Liliya
  • Tolosa, Guillermo
  • Casas, Irma|||0000-0002-5902-5777
  • Rosell Gratacos, Antoni|||0000-0003-0877-7191
  • Domínguez, José|||0000-0001-7888-0309
The measurement of specific T-cell responses can be a useful tool for COVID-19 diagnostics and clinical management. In this study, we evaluated the IFN-γ T-cell response against the main SARS-CoV-2 antigens (spike, nucleocapsid and membrane) in acute and convalescent individuals classified according to severity, and in vaccinated and unvaccinated controls. IgG against spike and nucleocapsid were also measured. Spike antigen triggered the highest number of T-cell responses. Acute patients showed a low percentage of positive responses when compared to convalescent (71.6% vs. 91.7%, respectively), but increased during hospitalization and with severity. Some convalescent patients showed an IFN-γ T-cell response more than 200 days after diagnosis. Only half of the vaccinated individuals displayed an IFN-γ T-cell response after the second dose. IgG response was found in a higher percentage of individuals compared to IFN-γ T-cell responses, and moderate correlations between both responses were seen. However, in some acute COVID-19 patients specific T-cell response was detected, but not IgG production. We found that the chances of an IFN-γ T-cell response against SARS-CoV-2 is low during acute phase, but may increase over time, and that only half of the vaccinated individuals had an IFN-γ T-cell response after the second dose.